Download En.CV - PubFacts

1
CURRICULUM VITAE
Name
Place and Date of Birth
Citizenship
Marital Status
ALBERTI SAVERIO
Arquà Polesine, Italy - Aug. 20. 1955.
Italian.
Single.
Degrees
1979: Medical Doctor, magna cum laude. Ferrara University School of Medicine. Ferrara, Italy.
1982: Specialist in Oncology, magna cum laude. Ferrara University School of Medicine. Ferrara,
Italy.
1982: PhD in Pharmacological Research. Institute Mario Negri, Milano, Italy.
1986: Specialist in Genetics. Stanford University. Stanford, USA.
Professional experience
1978 Aug-Sept: Clinical practice, Lutheran Medical Center, New York, NY, USA.
1980-1982: Research fellow, Laboratory of Oncology, Institute Mario Negri, Milano, Italy.
1980-1982: Specialty course in Clinical Oncology, Ferrara University School of Medicine.
Ferrara, Italy.
1980 Sept-1981 Feb: Residency, Oncology section, Niguarda Hospital. Milano, Italy.
1981: Training and authorization to work with laboratory animals, Istituto Mario Negri. Milano,
Italy.
1981: Training and authorization to work with radioactive materials, Istituto Mario Negri. Milano,
Italy.
1981 Oct-Nov: Visiting scientist, CRC, Transplantation Biology Section. Harrow, England.
1981: Training and authorization to work with laboratory animals, CRC, Transplantation Biology
Section. Harrow, England.
1983 Jan-Jun: Post-doctoral research affiliate, Laboratory of Human Genetics, Stanford
University, Stanford, USA.
1983-1986: Post-doctoral research affiliate, Laboratory of Immunogenetics, Stanford University,
Stanford, USA.
1983: Training and authorization to work with laboratory animals, Stanford University, Stanford,
USA.
1983: Training and authorization to work with radioactive materials, Stanford University,
Stanford, USA.
1986-1991: Senior scientist, Laboratory of Immunology, Institute Mario Negri, Milano, Italy.
1987 Aug-Sept: Visiting scientist, ILRAD, Nairobi, Kenya.
1988 Nov: Visiting scientist, RIKEN, Tsukuba, Japan.
1990 8 may-1999 31dec.: Region Lombardy (VIII level  31 oct. 1998; D3:  31 may 1999; D4:
31 dec. 1999).
1991-2003: Head, Laboratory of Experimental Oncology, Institute Mario Negri Sud. Santa Maria
Imbaro, Chieti, Italy.
1993-2000: Lecturer of Genetics and Biology, University of Bari, Bari, Italy.
1994 Mar-May: Visiting scientist, New York University, New York, NY, USA.
1994: Training and authorization to work with radioactive materials, New York University, New
York, NY, USA.
2
1996, 12 dec.-present: Visiting scientist, University of Anhui, China.
1997: Consultant, BD Biosciences - Pharmingen, San Diego, USA.
1998-2003: Lecturer, School of Clinical Oncology, Catholic University of Rome, Italy.
2000-2003: Consultant, Protein Design Laboratories, Fremont, USA.
2001-2008: Principal investigator, Development of anti-Trop-1 monoclonal antibodies, “New
radio-labeled anti-tumor drugs”, Sigma-Tau, Pomezia (Rome) – University of Chieti, Italy.
2002-2003: Consultant, National Cancer Institute–Veneto, Italy.
2004-present: Head, Group of Experimental Oncology, Unit of Cancer Pathology, University of
Chieti Foundation, Italy.
2003-2004: Lecturer, Molecular Oncology and Biotechnology, University of Chieti, Italy.
2003-present: Lecturer, Biology and Genetics of Metastases, Doctorate in Medical Oncology,
University of Chieti, Italy.
2004-present: Lecturer, Biotechnology in Pathology, School of Dentistry, University of Chieti,
Italy.
2004-2011: Scientific Board, ABO Foundation, Venice, Italy.
2005-2010: Lecturer, Specialty Scools in Oncology and Surgical Pathology, School of Medicine,
University of Ferrara, Italy.
2005-2010: Lecturer, Proteomics – Master in “Molecular pathology and tumor biotechnology”,
University of Ferrara, Italy.
2005-2010: Lecturer, In vivo and in vitro tumor models – Master in “Molecular pathology and
tumor biotechnology”, University of Ferrara, Italy.
2005-2010: Lecturer, Immunology – Master in “Molecular pathology and tumor biotechnology”,
University of Ferrara, Italy.
2005-2007: Council Member, Consortium for Advanced Diagnostic Imaging, Chieti, Italy.
2005-present: Lecturer, Biology of metastases: translational aspects in diagnostics and research.
Degree in Techniques for Biomedical Laboratories, University of Chieti, Italy.
2006-present: Lecturer “Molecular Oncology and Biotechnology”, School of Dentistry, University
of Chieti, Italy.
2006-2010: Scientific Officer, Research Training, “Research and development of food
technologies to generate mediterranean-diet nutraceutical for the prevention of aging-related
diseases“.
2007-2010: Co-Director – Master in “Molecular pathology and tumor biotechnology”, University
of Ferrara-Chieti, Italy.
2008-present: Co-Director, Unit of Cancer Pathology, University of Chieti Foundation, Italy.
2008-2012: Supervisor, PhD in Biotechnology – Neuroscience and Imaging, BAMS, University of
Chieti, Italy.
2008-present: Lecturer, PhD in Biotechnology – Neuroscience and Imaging, BAMS, University of
Chieti, Italy.
2009-present: Board Member, Spin-off & Patents Committee (CVRTT), University of Chieti,
Italy.
2010 Jan. 15: Founding Member, Oncoxx, Pescara, Italy.
2011: Board Member, Abruzzo Consortium for Trade Fairs, Lanciano (Chieti), Italy.
2011 Nov. 2-2013: President, Oncoxx, Pescara, Italy.
2011-present: Lecturer Molecular Genetics, School of Pharmacy, University of Chieti, Italy.
2012-present: Board Member, Exosomics, Siena, Italy.
2012 Sep. 13: Founding Member, Oncoxx Biotech, Chieti, Italy.
2012-present: President, Oncoxx Biotech, Chieti, Italy.
2012-2014: Project Manager & Scientific Director, Project “Future Medicine”, IPA Adriatic - EC.
2014, 7 jan.: National Board Certification, Sector 06/A1, Genetics, Associate Professor.
3
2014, 8 jan.: National Board Certification, Sector 06/A2, Pathology, Associate Professor.
2014, 1 jun.: National Board Certification, Sector 06/N1, Health Sciences and Applied Medical
Technologies, Associate Professor.
2014-present: Lecturer, PhD in Innovative Technologies – Medical Biotechnology, University of
Chieti, Italy.
2014, 1 jul.: National Board Certification for Public Administration. Assigned level: 1st.
2015: Lecturer, Genetics, School of Nursing, University of Chieti, Italy.
Positions:
- Co-Director, Unit of Cancer Pathology, University of Chieti Foundation, Italy.
- President, Oncoxx Biotech, Chieti, Italy.
- Board Member, Exosomics, Siena, Italy.
- Board Member, Spin-off & Patents Committee, University of Chieti, Italy.
- Lecturer, University of Chieti, Italy.
- Project Manager & Scientific Director, Project “Made in Italy – Next-generation sequencing”,
Italian Ministry of Development.
- Principal Investigator, Project “Smart Cities – Health@Home”, Italian Ministry of Research.
4
Duties
Referee of EMBO Molecular Medicine.
Referee of Cancer Research.
Referee of Clinical Cancer Research.
Referee of Neoplasia.
Referee of Oncotarget.
Referee of FEBS letters.
Referee of Biochemical Biophysical Acta.
Referee of Biochemical Biophysical Acta – Reviews on Cancer.
Referee of Molecular Cancer Therapeutics.
Referee of Experimental Cell Research.
Referee of Trends in Molecular Medicine.
Referee of American Journal of Physiology.
Referee of International Journal of Cancer.
Referee of Scientific Reports.
Referee of European Journal of Cancer.
Referee of BMC Cancer.
Referee of Breast Cancer Research and Treatment.
Referee of Cancer Epidemiology Biomarkers & Prevention.
Referee of Cell Death and Disease.
Referee of European Journal of Pharmacology.
Referee of Cellular and Molecular Life Sciences.
Referee of PlosOne.
Referee of Cancers.
Referee of American Association for Science and Technology.
Referee of BioMedCentral Biotechnology.
Referee of Bentham Science Publishers.
Referee of Molecular Cancer Therapy.
Referee of Carcinogenesis.
Referee of Cancer Informatics.
Referee of Cancer Causes and Control.
Referee of Journal of Biological Markers.
Referee of Tumor Biology.
Referee of Translational Oncology.
Referee of Disease Markers.
Referee of Journal of Cancer Research and Clinical Oncology.
Referee of Nutrition Research.
Referee of Molecular Biology and Evolution.
Referee of Current Pharmaceutical Design.
Referee of British Journal of Medicine and Medical Research.
Referee of Letters in Drug Design and Discovery.
Referee of Molecular Medicine Reports.
Referee of Recent Patents on Biomarkers.
Referee of Chinese Journal of Cancer Research.
Referee of Archives of Medical Science.
Referee of Tumori.
Referee of Archives Italiennes de Biologie.
Editor of Critical Reviews in Oncogenesis.
5
Editor of Molecular Medicine Reports.
Editor of Stem Cell Epigenetics.
Editor of Frontiers in Bioscience.
Project reviewer for the European community – ERA-NET TRANSCAN.
Project reviewer for the Association for International Cancer Research, UK.
Project reviewer for the French National Research Agency ANR, France.
Project reviewer for the Health Research Council of New Zealand.
Project reviewer for the Estonian Science Foundation, Estonia.
Project reviewer for the Czech Science Foundation, Czech Republic.
Project reviewer for the Italian Association for Cancer Research.
Project reviewer for the Ministry of the University and Scientific Research (PRIN).
Project reviewer for the Ministry of the University and Scientific Research (Future in Research).
Project reviewer for the Ministry of the University and Scientific Research (Centers of
Excellence).
Project reviewer for the Ministry of the University and Scientific Research (FIRB).
Project reviewer for the Ministry of the University and Scientific Research (CIVR).
Patents
1. PCT: E. Guerra and S. Alberti “Humanized anti-Trop-2 monoclonal antibodies and uses
thereof” - WO2016087651 A1, International Publication Date 9 June 2016, International
filing date 4 Dec 2015.
2. Patent: E. Guerra e S. Alberti “Humanized Anti-Trop-2 Monocolonal Antibodies and Uses
Thereof”. IT patent application CH2014A000032; filing date 4 Dec 2014.
3. Patent: S. Alberti e E. Guerra “Use of Serum Circulating Trop-2 as New Tumor Biomarker”
Patent application 102015000074105; filing date 18 Nov 2015.
4. PCT: S. Alberti and E. Guerra “Use of Trop-2 as predictive marker of response to anti-tumor
therapy based on inhibitors of CD9, Akt and molecules of the tetraspanin signalling network” PCTIIT2013/ WO2013171777 International filing date 6 May 2013; Granted IT patent
M12516Q3131; pending in EP, US, CA, AU, JP, CN, IN.
5. Patent: S. Alberti "Oligonucleotide sequences that inhibit the expression of chimeric
mRNA that control the growth of tumor cells and their use in the medical field" - applied
for in Chieti on the 12th Nov. 2012. SIMBA N° CH2012A000016.
6. Patent: S. Alberti and E. Guerra “Use of Trop-2 as a predictive marker of response to antitumor therapy based on inhibitors of CD9 and Akt and molecules of the tetraspanin
signalling network” - applied for in Chieti on the 16th May 2012. Application N°
M12516Q3131; SIMBA N° CH2012A000008; protocol N° 175000-AOO021-140.
7. PCT: S. Alberti and E. Guerra “Oligonucleotide sequences able to silence the expression of
the CYCLIN D1/TROP2 chimera and use thereof in the medical field” WO2010035304
International filing date 25 Set 2009; Granted US patent US 8,507,664; Granted EP patent
EP2342342; Granted AU patent AU2009297961B; Granted IT patent 0001398773; pending in
JP, CA.
8. PCT: S. Alberti “Anti-Trop-2 monoclonal antibodies and uses thereof in the treatment and
diagnosis of tumors” WO2010089782 International filing date 5 Feb 2009; Granted US patent
US 8,715,662 on 6 may 2014; granted IT patent CH07A000018; Granted AU patent
AU2009339664B; pending in EP, CA, CN, JP.
6
9. Patent: S. Alberti and E. Guerra "Use of a CYCLIN D1/TROP2 fusion mRNA for tumor
diagnosis and therapy” - applied for in Chieti on the 25th Sep. 2008. Application N°
M08925Q2218; protocol N° 175000-A000021-0000132.
10. PCT/EP: A. Anastasi, F. Petronzelli, S. Alberti, R. De Santis “Anti-EpCAM antibody and
uses thereof” (548/PCT/EPBS000R548) – applied for on the 2nd Apr. 2008; granted on the
15th june 2011 #2142570; 548-PCT-US, granted on the 28th Nov. 2012 as US8318911B2.
11. Patent: S. Alberti “Anti-Trop-2 antibodies and related use” – applied for in Chieti
(Application number CH07A000018) on the 6th Aug. 2007.
12. Patent: S. Alberti “New technologies for the analysis of the proteome” – applied for in
Chieti (Application number CH05A000007) on the 14th Apr. 2005; granted on the 10th
jul. 2009 - N° 0001363767.
13. Patent: S. Alberti and A. Sese “Nucleic Acids Sensors” – applied for in Chieti (Italy)
(Application number CH02A000009) on the 16th Sep. 2002; granted on the 23rd feb. 2006
- N° 0001332234.
14. Patent: S. Alberti, A. Mercuri, T. Schiva and V. Ciccolella “Fluorescent Flowers” –N°
BA01A00051, applied for in Bari (Italy) on the 16th Oct. 2001.
Licenses
1997: S. Alberti pRK-5-C-GFP and the pRK-5-N-GFP mammalian expression vectors, to BD
Biosciences-Pharmingen, San Diego, USA.
2013: S. Alberti, Oncoxx Biotech, 2EF and 2G10 monoclonal anti-Trop-2 antibodies, to
Millipore-Merck, USA.
Software
2010: TFinder (recognition of transcription factors-DNA bonds).
2011: FusionMiner (retrieval of chimeric oncogenic mRNA from sequence data-sets).
Honors and Fellowships
1978: Italo-American Medical Education Foundation.
1979: Giuseppe Previtali Award.
1979: Dora Nicita Award.
1981: Wellcome Foundation.
1982: Rotary Foundation.
1982: Italian Association for Cancer Research.
1982: Sigma-Tau Award.
1983: Italian Association for Cancer Research.
1983: European Community - Ministry of Labor.
1984: Corrado Montemaggiori Award.
1984: Italian Association for Cancer Research.
1987: European Federation of Immunological Societies.
1993: European Association for Cancer Research.
1994: International Union Against Cancer.
2006: MSD-EACR Research Award (best basic science research).
2007: 12th World Congress on Advances in Oncology Award (best presentation).
2008: Chieti Chamber of Commerce Prize (best patent of the year).
2008: Paul Harris Fellow of the Rotary Foundation.
7
2011: Prize “Medicina Abruzzo”, 3rd Editon.
2011: 1st place, Oncoxx, Innova Day Start-Up Program, Biomed-Biotech Business Matching
Event, Mirandola (Modena) 27 May 2011.
2011: 1st place, Oncoxx, Intesa Sanpaolo Start-Up Initiative – 3 Nov. 2011 Frankfurt (Germany).
2013: Prize “Medicina Abruzzo” 5th Edition.
2014: Oncoxx Biotech – “Top 100” start-ups in Italy.
2015: Oncoxx Biotech – “Top 100” start-ups in Italy.
Societies
International Union Against Cancer (permanent member).
American Association for Cancer Research.
American Society of Clinical Oncology.
European Association for Cancer Research.
DNA Methylation Society.
Italian Association for Cancer Research.
Italian Society for Cytometry.
StemTeCh.
Meetings organization:
Alberti S., Erba E. e Poggi A. IX Riunione nazionale di citometria - “La citometria tra ricerca di
base e clinica” Consorzio Mario Negri Sud, Santa Maria Imbaro (Chieti) 13-16 Ottobre 1992.
Alberti S. Workshop – “Frontiere terapeutiche ed indicatori prognostici molecolari in oncologia”
International Cancer Center, Rovigo, 25 Maggio 2001.
Alberti S., Gion M. e Colacci A. Workshop – “Marcatori Molecolari Emergenti in Oncologia :
Terapia mirata, Indicatori di Risposta, Chemioprevenzione” International Cancer Center, Rovigo,
20 Settembre 2002.
Alberti S., Parodi S. Workshop – “Mutazioni di oncogeni in tumori nell’ uomo - nuove tecnologie
e applicazioni cliniche”, Foundation University “G. D’ Annunzio”, CeSI, Chieti, 18 sep. 2007.
Alberti S., et al. European Biotechnology Congress, Lecce, 15-18 may 2014.
8
ARTICLES
1. Grossi M.P., Meneguzzi G., Chenciner N., Corallini A., Poli F., Altavilla G., Alberti S.,
Milanesi G. and Barbanti-Brodano G. Lack of association between BK virus and
ependymomas, malignant tumors of pancreatic islets, osteosarcomas and other human
tumors. Intervirology, 15: 10 (1981).
IF = 1.773
2. Alberti S., Boraschi D., Luini W. and Tagliabue A. Effects of in vivo treatments with
Cyclosporin-A on mouse cell-mediated immune responses. Int. J. Immunopharmacol., 3:
357 (1981). (Now “International Immunopharmacology”)
IF = 2.711
3. Luini W., Boraschi D., Alberti S., Aleotti A. and Tagliabue A. Morphological
characterization of a cell population responsible for natural killer activity. Immunology,
43: 663 (1981).
IF = 3.735
4. Altavilla G., Carrà L., Alberti S., Corallini A., Cavazzini L., Fabris G., Aleotti A. and
Barbanti-Brodano G. BK virus-induced tumors in hamsters: a morphological,
histochemical and ultrastructural study. Oncology 40: 427 (1983).
IF = 2.613
5. Acero R., Polentarutti N., Bottazzi B., Alberti S., Ricci M. R., Bizzi A. and Mantovani A.
Effect of hydrocortisone on the macrophage content, growth and metastasis of transplanted
murine tumors. Int. J. Cancer 33: 95 (1984).
IF = 5.007
6. Alberti S., Stovel D. and Herzenberg L. A. Preservation of cells sorted individually onto
microscope slides with a fluorescence-activated cell sorter. Cytometry 5: 644 (1984).
IF = 3.066
7. Herzenberg L. A., Hsu C., Alberti S. and Kavathas P. Transfection and cloning of genes
for membrane antigens using the FACS. Med. Oncol. Tum. Pharmacother. 1 (4): 219
(1984).
IF = 0.944
8. Alberti S., Luini W., Pasqualetto E., Allegrucci M., Spreafico F., Patterson S., Grindley
H., Alberti E. and Colotta F. Relationship between large granular lymphocytes and NK-1.2
+ cells from normal and poli-IC treated mice. Clin. Immunol. Immunopathol. 36: 81
(1985). (Now ”Clinical Immunology”)
IF = 3.992
9. Alberti S., Colotta F., Spreafico F., Delia D., Pasqualetto E. and Luini W. Large granular
lymphocytes from murine blood and intestinal epithelium: comparison of surface antigens,
natural killer activity and morphology. Clin. Immunol. Immunopathol. 36: 227 (1985).
(Now ”Clinical Immunology”)
IF = 3.992
9
10. Alberti S., Filippeschi S., Spreafico F., Alberti E. and Colotta F. Metastatic growth of a
murine tumor: evidence of dissemination to the lungs in the absence of subcutaneous
growth. Tumori 72(4):345-50 (1986).
IF = 1.09
11. Alberti S. and Herzenberg L. A. DNA transfection: gene regulation, gene amplification
and gene cloning. Juntendo Med. J. 32 (4): 423 (1986).
12. Alberti S., Parks D. R. and Herzenberg L. A. A single laser method for subtraction of cell
autofluorescence in flow cytometry. Cytometry 8: 114 (1987).
IF = 3.066
13. Alberti S. and Herzenberg L. A. DNA methylation prevents transfection of genes for
specific surface antigens. Proc. Natl. Acad. Sci. USA 85: 8391 (1988).
IF = 9.809
14. Alberti S. and Fornaro M. Higher transfection efficiency of genomic DNA purified with a
guanidinium thiocyanate-based procedure. Nucl. Acids Res. 18 (2): 351 (1990).
IF = 8.808
15. Klein C. E., Hartmann B., Schön M. P., Weber L. and Alberti S. Expression of a 38 kD
cell surface glycoprotein in transformed human keratinocyte cell lines, basal cell
carcinomas and epithelial germs. J. Invest. Dermatol. 95: 74 (1990).
IF = 6.372
16. Toye P.G., Machugh N.D., Bensaid A.M., Alberti S., Teale A.J. and Morrison W.I.
Transfection into mouse L cells of genes encoding two serologically and functionally
distinct bovine class I MHC molecules from a MHC-homozygous animal: evidence for a
second class I locus in cattle. Immunology 70: 20 (1990).
IF = 3.735
17. Alberti S., Miotti S., Fornaro M., Mantovani L., Walter S., Canevari S., Ménard S. and
Colnaghi M. I. The Ca-MOv18 molecule, a cell surface marker of human ovarian
carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem. Biophys.
Res. Comm. 171: 1051 (1990).
IF = 2.281
18. Alberti S., Bucci C., Fornaro M., Robotti A. and Stella M. Immunofluorescence Analysis
in Flow Cytometry: Better Selection of Antibody-Labeled Cells after Fluorescence
Overcompensation in the Red Channel. J. Histochem. Cytochem. 39: 701 (1991).
IF = 2.403
19. Lalor P., Bucci C., Fornaro M., Rattazzi M.C., Nakauchi H., Herzenberg L.A. and Alberti
S. Molecular cloning, reconstruction and expression of the gene encoding the alpha chain
of the bovine CD8 - Definition of three peptide regions conserved across species.
Immunology 76: 95 (1992).
IF = 3.735
10
20. Vermeer L., Bos N., Bucci C., Kroese F. and Alberti S. Molecular cloning of the rat CD5
gene. Ann. N. Y. Acad. Sci. 651: 82 (1992).
IF = 4.313
21. Jonjic N., Alberti S., Bernasconi S., Peri G., Jìlek P., Anichini A., Parmiani G. and
Mantovani A. Heterogeneous susceptibility of human melanoma clones to monocyte
cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. Eur. J.
Immunol. 22: 2255-2260 (1992).
IF = 4.518
22. Miotti S., Alberti S., Mantovani L., Facheris P., Fornaro M., Stella M., Ménard S.,
Canevari S. and Colnaghi M.I. Membrane association and shedding of the GPI-anchored
CaMOv18 antigen in human ovary carcinoma cells. Int. J. Cancer 51: 499 (1992).
IF = 5.007
23. Alberti S., Miotti S., Stella M., Klein C.E., Fornaro M., Ménard S. and Colnaghi M. I.
Biochemical characterization of Trop-2, a cell surface molecule expressed by human
carcinomas: Formal proof that the monoclonal antibodies T16 and MOv-16 recognize
Trop-2. Hybridoma 11: 539 (1992).
IF = 0.244
24. Anichini A., Mortarini R., Alberti S., Mantovani A. and Parmiani G. T-cell-receptor
engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of
melanoma cells to autologous CTL-mediated lysis. Int. J. Cancer 53: 994-1001 (1993).
IF = 5.007
25. Schön M. P., Schön M., Mattes M. J., Stein R., Weber L., Alberti S. and Klein C. E.
Biochemical and immunological characterization of the human carcinoma-associated
antigen MH99 /KS1/4. Int. J. Cancer 55: 988 (1993).
IF = 5.007
26. Kaufmann R., Hainzl A., Sterry W., Sonnenberg A., Alberti S. and Klein C. E. Klein
Integrin receptor molecules in human skin xenografts are selectively bound by
intravenously applied anti-integrin antibodies. Arch. Dermatol. Res. 286: 6 (1994).
IF = 2.27
27. Vermeer L. A., de Boer N. K., Bucci C., Bos N. A., Kroese F. G. M. and Alberti S. MRC
OX19 recognizes the rat CD5 surface glycoprotein, but does not provide evidence for the
presence of a distinct CD5 positive B cell population in the rat. Eur. J. Immunol. 24: 585
(1994).
IF = 4.518
28. Alberti S., Nutini M. and Herzenberg L. A. DNA methylation prevents the amplification
of TROP1, a tumor-associated cell surface antigen gene. Proc. Natl. Acad. Sci. USA 91:
5833 (1994).
IF = 9.809
29. Fornaro M., Dell’ Arciprete R., Stella M., Bucci C., Nutini M., Capri M. G. and Alberti S.
Cloning of the gene encoding Trop-2, a cell surface glycoprotein expressed by human
11
carcinomas. Int. J. Cancer 62: 610-618 (1995).
IF = 5.007
30. Dell’ Arciprete R., Stella M., Fornaro M., Ciccocioppo R., Capri M. G., Naglieri A. M.
and Alberti S. High efficiency expression gene cloning by flow cytometry. J. Histochem.
Cytochem. 44: 629-640 (1996).
IF = 2.403
31. Alberti S. Development of ulcerative colitis: evidence from animal models. Mol. Med.
Today 2: 272-274 (1996). (Now ”Trends in Molecular Medicine”)
IF = 10.11
32. Alberti S. A high affinity T cell receptor? Immunol. Cell Biol. 74: 292-297 (1996).
IF = 4.205
33. Guillaudeux T., Gomez E., Onno M., Drénou B., Segretain D., Alberti S., Lejeune H.,
Fauchet R., Jégou B. and Le Bouteiller P. Expression of HLA class I genes in meiotic and
post-meiotic human spermatogenic cells. Biol. Reproduct. 55: 99-110 (1996).
IF = 3.451
34. Ciccocioppo R., Capri M. G.and AlbertiS. Detection of the Receptor for the Human
urokinase-type Plasminogen Activator using Fluoresceinated uPA. J. Histochem.
Cytochem. 45: 1307-1313 (1997).
IF = 2.403
35. Alberti S. Novel drugs and strategies for gastrointestinal disorders. Meeting report. IBC
conference "Gastrointestinal disorders: current understanding, new approaches to
prevention and treatment". Royal Society, London, UK. June 23-24 (1997). Mol. Med.
Today 3 (8): 416-417 (1997). (Now ”Trends in Molecular Medicine”)
IF = 10.11
36. Alberti S. The origin of the genetic code and of protein synthesis. J. Mol. Evol. 45 (4):
352-358 (1997).
IF = 1.863
37. Ciccocioppo R, Dell'Arciprete R, Marra P, Alberti S. Comparative analysis of wildtype
and mutant forms of GFP. Eur J Histochem. 41 Suppl 2:97-8 (1997).
IF = 2.237
38. El-Sewedy T., Fornaro M. and Alberti S. Cloning of the mouse Trop2 gene - Conservation
of a PIP2-binding sequence in the cytoplasmic domain of Trop-2. Int. J. Cancer 75: 324331 (1998).
IF = 5.007
39. Alberti S. A Phosphoinositide-binding Sequence is shared by PH Domain Target
Molecules. - A Model for the Binding of PH Domains to Proteins. Proteins 31: 1-9 (1998).
IF = 2.921
40. Ripani E., Sacchetti A., Corda D. and Alberti S. The human Trop-2 is a tumor-associated
12
calcium signal transducer. Int. J. Cancer 76: 671-676 (1998).
IF = 5.007
41. Alberti S. Distinguishing ulcerative colitis from autoimmunity. Mol. Med. Today 4: 188
(1998). (Now ”Trends in Molecular Medicine”)
IF = 10.11
42. Alberti S. HIKE, a candidate protein binding site for PH domains, is a major regulatory
region of Gb proteins. Proteins 35 (3): 360-3 (1999).
IF = 2.921
43. Sacchetti A., Crescenzi C., Cappetti V., Celli N., Rotilio D.and Alberti S. Red GFP and
endogenous porphyrins. Curr. Biol. 9 (11): 391-3 (1999).
IF = 9.916
44. Spanò S., Silletta M. G., Colanzi A., Alberti S., Fiucci G., Valente C., Fusella A., Salmona
M., Mironov A., Luini A., Corda D. Molecular cloning and functional characterization of
brefeldin A-ADP-ribosylated substrate. A novel protein involved in the maintenance of the
Golgi structure. J. Biol. Chem. 274 (25): 17705-10 (1999).
IF = 4.6
45. Sacchetti A. and Alberti S., Protein tags enhance GFP folding in eukaryotic cells. Nature
Biotechnology 17: 1046 (1999).
IF = 39.08
46. Alberti S. The evolution of the genetic code, protein synthesis and nucleic acids
replication. Cell. Mol. Life Sci. 56: 85:93 (1999).
IF = 5.856
47. Sacchetti A., Ciccocioppo R. and Alberti S. The Molecular Determinants of the Efficiency
of Green Fluorescent Protein Mutants. Histol. Histopathol. 15 (1): 101-107 (2000).
IF = 2.236
48. Polishchuk R.S., Polishchuk E.V., Marra P., Alberti S., Buccione R., Luini A. and
Mironov A. Correlative light-electron microscopy reveals the tubular-saccular
ultrastructure of carriers operating between Golgi apparatus and plasma membrane. J. Cell.
Biol. 148: 45-58 (2000).
IF = 9.688
49. Ciccarelli F., Acciarito A. and Alberti S. Large and diverse numbers of human diseases
with HIKE mutations. Hum. Mol. Genet. 9:1001-1007 (2000).
IF = 6.677
13
50. Calabrese G., Crescenzi C., Morizio E., Palka G., Guerra E., Alberti S. Assignment of
TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping
of the TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ
hybridization. Cytogenet. Cell Genet. 92(1-2):164-5 (2001). (Now “Cytogenetic and
Genome Research”)
IF = 1.905
51. Terrinoni A., Dell’ Arciprete R., Fornaro M., Stella M. and Alberti S. The Cyclin D1 gene
contains a cryptic promoter that is functional in human cancer cells. Genes Chromosomes
Cancer 31(3): 209-220 (2001).
IF = 3.836
52. Sacchetti A., Cappetti V., Marra P., Dell'Arciprete R., El-Sewedy T., Crescenzi C. and
Alberti S. Green Fluorescent Protein variants fold differently in prokaryotic and
eukaryotic cells. J. Cell. Biochem. 36: 117-128 (2001).
IF = 3.368
53. Balzar M., Briaire-de Bruijn I.H., Rees-Bakker H.A.M., Prins F.A., Hellfrich W., de Leij
L., Riethmuller G., Alberti S., Warnaar S.O., Fleuren G.J., and Litvinov S.V. Epidermal
Growth Factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM
molecules in homophylic adhesions. Mol. Cell. Biol. 21(7): 2570-2580 (2001).
IF = 5.036
54. Sacchetti A., El-Sewedy T., Nasr A. F. and Alberti S. Efficient GFP mutations profoundly
affect mRNA transcription and translation rates. FEBS letters 9; 492(1-2): 151-5 (2001).
IF = 3.341
55. Mercuri A., Sacchetti A., De Benedetti L., Schiva T. and Alberti S. Green Fluorescent
Flowers. Plant Science 161 (5) 961– 968 (2001) [corrigendum: Plant Science 162 (4) 647654 (2002)].
IF = 4.114
Discussed in: Nature, 24 oct. 2001; Newsweek, 9 dec. 2001; Der Spiegel, nov.
2001; Max, dec. 2001; Il Venerdì di Repubblica dec. 2001; La Stampa, 3 gen.
2002; Il Secolo XIX, 14 nov. 2001; Imperia-San Remo, 14 nov. 2001; Flortecni
dec. 2001; Riviera-Cote d’ Azur Zeitung, 1 jan. 2002.
56. Guerra E. and Alberti S. Molecular prognostic indicators for breast cancer. Tumori 87:
S23-25 (2001).
IF = 1.09
57. Alberti S. Trop molecules as targets for anti-tumor immunotherapy in man. Tumori 87:
S5-8 (2001).
IF = 1.09
58. Sacchetti, A., Cappetti, V., Marra, P., Dell'Arciprete, R., El Sewedy, T., Crescenzi, C.,
Alberti, S. Nuclear changes in necrotic HL-60 cells. Journal of Cellular Biochemistry 81
(S36): 19-31 (2001).
IF = 3.368
14
59. Sacchetti A., Subramaniam V., Jovin T. M. and Alberti S. Oligomerization of DsRed is
required for the generation of a functional red fluorescent chromophore. FEBS letters 525
(1-3): 13-19 (2002).
IF = 3.341
60. Mangino G., Capri M. G., BarnabaV. and Alberti S. Presentation of native Trop-2 tumor
antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int. J.
Cancer 101(4):353-9 (2002) (with cover picture of the issue).
IF = 5.007
61. Nasr A. F., Nutini M., Palombo B., Guerra E. and Alberti S. Mutations ofTP53 induce loss
of DNA methylation and amplification of the TROP1 gene. Oncogene 22: 1668-77 (2003).
IF = 8.559
62. Guerra E., Vacca G., Palombo B. and Alberti S. Prognostic value of mutations of TP53
and RAS genes in breast cancer. Int. J. Biol. Markers 18: 49-53 (2003).
IF = 1.36
63. Alberti S. and Parodi S. Signaling proteins as targets of new anti-neoplastic drugs Int. J.
Biol. Markers 18: 57-61 (2003).
IF = 1.36
64. Romani A., Guerra E., Trerotola M. and Alberti S. Detection and analysis of spliced
chimeric mRNAs in sequence databanks. Nucl. Acids Res. 31 (4 e17): 1-8 (2003).
IF = 8.808
65. Cimoli G., Malacarne D., Ponassi R., Valenti M., Alberti S. and Parodi S. Meta analysis
of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim. Biophys. Acta – Rev. Cancer 1705: 103– 120 (2004).
IF = 7.584
66. Ambrogi F., Biganzoli E., Querzoli P., Ferretti S., Boracchi P., Alberti S., Marubini E.,
Nenci I. Molecular subtyping from traditional tumor marker profiles using parallel
clustering methods. Clin. Cancer Res.12(3): 781-790 (2006).
IF = 8.722
67. Tinari N., Lattanzio R., Natoli C., Cianchetti E., Angelucci D., Ricevuto E., Ficorella C.,
Marchetti P., Alberti S., Piantelli M., Iacobelli S. Changes of topoisomerase IIalpha
expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Clin. Cancer Res. 12(5):1501-1506 (2006).
IF = 8.722
68. Piantelli M., Rossi C., Iezzi M., La Sorda R., Iacobelli S., Alberti S. and Natali P.G.
Flavonoids inhibit melanoma lung metastases by impairing tumor cell-endothelium
interactions. J. Cell Physiol. 207: 23-29 (2006).
IF = 3.874
69. Querzoli P., Pedriali M., Rinaldi R., Lombardi A.R., Biganzoli E., Boracchi P., Ferretti S.,
Frasson C., Zanella C., Ghisellini S., Ambrogi F., Antolini L., Piantelli M., Iacobelli S.,
15
Marubini E., Alberti S.and Nenci I. Axillary lymph node nanometastases are prognostic
factors for disease-free survival and metastatic relapse in breast cancer patients. Clin.
Cancer Res. 12: 6696-6701 (2006) (corresponding author).
IF = 8.722
Plenary lecture, SABCS, San Antonio (TX) 14-17 Dec. 2006.
Debated in Oncology News Int. (Feb. 2007).
Presented in “Highlights from the 29th annual San Antonio Breast Cancer
Symposium”, 2007, p. 6
Debated in JNCI 99(10): 751-3 (2007).
70. Carletti E., Guerra E. and Alberti S. The forgotten variables of DNA array hybridization.
Trends Biotech. 24 (10): 443-448 (2006).
IF = 10.04
71. Zanna P., Trerotola M., Vacca G., Bonasera V., Palombo B., Guerra E., Rossi C.,
Lattanzio R., Piantelli M. and Alberti S. Trop-1 are conserved growth stimulatory
molecules that mark early stages of tumor progression. Cancer 110 (2): 452-464 (2007).
IF = 4.901
72. Bonasera V., Alberti S. and A. Sacchetti A. Protocol for high-sensitivity/long linear-range
spectrofluorimetric DNA quantification using ethidium bromide. BioTechniques 43 (2):
173-176 (2007) (corresponding author).
IF = 2.754
73. Marabotti A., Spyrakis F., Facchiano A.,Cozzini P., Alberti S., Kellogg G.E., Mozzarelli
A. Energy-based prediction of amino acid-nucleotide base recognition. J. Comp. Chem.
29(12): 1955-1969 (2008).
IF = 3.601
74. Guerra E., Trerotola M., Dell’ Arciprete R., Bonasera V., Palombo B., El-Sewedy T.,
Ciccimarra T., Crescenzi C., Lorenzini F., Rossi C., Vacca G., Lattanzio R., Piantelli M.
and Alberti S. A bi-cistronic Cyclin D1-TROP2 mRNA chimera demonstrates a novel
oncogenic mechanism in human cancer. Cancer Res. 68: (19): 8113-8121 (2008).
IF = 9.284
75. Rossi C., Di Lena A., Lasorda R., Lattanzio R., Antolini L., Patassini C., Piantelli M. and
Alberti S. Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates
the growth of breast cancer. Eur. J. Cancer 44: 2696 –2704 (2008).
IF = 4.819
76. Tinari N.,Lattanzio R., Querzoli P., Natoli C., Grassadonia A., Alberti S., Hubalek M.,
Reimer D., Nenci I., Bruzzi P., Piantelli M. and Iacobelli S., on behalf of the Consorzio
Interuniversitario Nazionale per la Bio-Oncologia (CINBO). High expression of 90K
(Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not
receiving adjuvant systemic therapies. Int. J. Cancer 124: 333–338 (2009).
IF = 5.007
77. Weidle U. H., Evtimova V., Alberti S., Guerra E., Fersis N. and Kaul S. Cell Growth
16
Stimulation by CRASH, an Asparaginase-like Protein Overexpressed in Human Tumors
and Metastatic Breast Cancers. Anticancer Res. 29: 951-964 (2009).
IF = 1.872
78. Trerotola M., Guerra E. and Alberti S. Efficacy and safety of anti-Trop antibodies. BBA
Rev. Cancer 1805: 119–120 (2010).
IF = 7.584
79. Biganzoli E., Pedriali M., Querzoli P., Nenci I., Iacobelli S., Piantelli M. and Alberti S.
Sentinel Node and Bone Marrow Micro and Nanometastases. Curr. Breast Cancer Rep. 2:
96–106 (2010).
IF = to be determined
80. Trerotola M., Rathore S., Goel H.L., Li J., Alberti S., Piantelli M., Adams D., Jiang Z. and
Languino L.CD133, Trop-2 and α2β1 Integrin Surface Receptors as Markers of Putative
Human Prostate Cancer Stem Cells. Am. J. Transl. Res. 2 (2): 135-44 (2010).
IF = 3.226
81. Sukhthankar M., Alberti S. and Seung Joon Baek S. J. (-)-Epigallocatechin-3-Gallate
(EGCG) Post-transcriptionally and Post-translationally Suppresses the Cell Proliferative
Protein Trop-2 in Human Colorectal Cancer Cells. Anticancer Res. 30 (7): 2497-503
(2010).
IF = 1.872
82. Pannellini T., Iezzi M., Liberatore M., Sabatini F., Iacobelli S., Rossi R., Alberti S., Di
Ilio C., Vitaglione P., Fogliano V. and Mauro Piantelli M. A dietary tomato supplement
prevents prostate cancer in TRAMP mice. Cancer Prev. Res. 3(10): 1284-91(2010).
IF = 5.269
83. Querzoli P., Coradini D., Pedriali M., Boracchi P., Ambrogi F., Raimondi E., La Sorda R.,
Lattanzio R., Rinaldi R., Lunardi M., Frasson C., Modesti F., Ferretti S., Piantelli M.,
Iacobelli S., Biganzoli E, Nenci I. and Alberti S. An immunohistochemically positive Ecadherin status is not always predictive for a good prognosis in human breast cancer. Br. J.
Cancer 103 (12): 1835-9 (2010).
IF = 4.817
84. Biganzoli E., Coradini D., Ambrogi F., Garibaldi J., Lisboa P., Soria D., Green A., Pedriali
M., Piantelli M., Querzoli P., Demicheli R., Boracchi P., Nenci I., Ellis I. and Alberti S.
p53 Status Identifies Two Distinct Subgroups of Triple-Negative Breast Cancers. Jpn. J.
Clin. Oncol. 41 (2): 172-9 (2011).
IF = 1.747
85. Vergara D., Simeone P., Toraldo D., Del Boccio P., Vergaro V., Leporatti S., Pieragostino
D., Tinelli A., De Domenico S., Alberti S., Urbani A., Salzet M., Santino A. and Maffia
M. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3
ovarian cancer cells. Mol Biosyst. 8: 1078–87 (2012).
IF = 3.183
17
86. Plebani R., Oliver G.R., Trerotola M., Guerra E., Cantanelli P., Emerson A., Harkin P.D.,
Kennedy R.D. and Alberti S. Long-range transcriptome sequencing reveals cancer cell
growth regulatory chimeric mRNA. Neoplasia 14 (11): 1087-1096 (2012).
IF = 5.398
87. Trerotola M., Li J., Alberti S.and Languino L.R. Trop-2 inhibits prostate cancer cell
adhesion to fibronectin through the β1 integrin-RACK1 axis. J. Cell Physiol. 227(11):
3670-7 (2012).
IF = 3.874
88. Alberti S., Ambrogi F., Boracchi P., Fornili M., Querzoli P., Pedriali M., La Sorda R.,
Lattanzio R.,Tripaldi R.,Piantelli M., Biganzoli E. and Coradini D. Cytoplasmic Trop1/Ep-CAM over-expression is associated with a favorable outcome in node-positive breast
cancer Jpn. J. Clin. Oncol. 42 (12):1128-37 (2012).
IF = 1.747
89. Guerra E., Lattanzio R., La Sorda R., Dini F., Piantelli M., Tiboni G.M. and Alberti S.
mTrop1/EpCAM knockout mice develop congenital tufting enteropathy through
disregulation of intestinal E-cadherin/β-catenin. PLoS One 7 (11): 1-9 e49302 (2012).
IF = 3.534
90. Trerotola M., Cantanelli P., Guerra E., Tripaldi R., Aloisi A.L., Bonasera V., Lattanzio R.,
de Lange R., Weidle U.H., Piantelli M. and Alberti S. Up-regulation of Trop-2
quantitatively stimulates human cancer growth. Oncogene 32: 222-233 (2013).
IF = 8.559
91. Ambrogi F., Fornili M., Alberti S., Querzoli P., Piantelli M., Pedriali M., Boracchi P.,
Biganzoli E. and Coradini D. EpCAM Expression is an Indicator of Increased Incidence of
Relapse in p53-Positive Breast Cancer. Cancer Clin. Oncol. 2 (1): 41-50 (2013).
IF = to be determined
92. Guerra E., Trerotola M., Aloisi A.L., Tripaldi R., Vacca G., La Sorda R., Lattanzio R.,
Piantelli M. and Alberti S. The Trop-2 signalling network in cancer growth Oncogene 32:
1594-1600 (2013).
IF = 8.559
93. Lattanzio R., Marchisio M., La Sorda R., Tinari N., Falasca M., Alberti S., Miscia S.,
Ercolani C., Di Benedetto A., Perracchio L., Melucci E., Iacobelli S., Mottolese M., Natali
P. G. and Piantelli M. Overexpression of activated phospholipase Cγ1 is a risk factor for
distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.
Int. J. Cancer 132: 1022-31 (2013).
IF = 5.007
94. Tripaldi R., Stuppia L. and Alberti S. Human height genes and cancer. BBA Reviews on
Cancer 1836 (1): 27–41 (2013).
IF = 7.584
95. Vergara D., Simeone P., del Boccio P., Toto C., Pieragostino D., Tinelli A., Acierno R.,
Alberti S., Salzet M., Giannelli G., Sacchetta P., Maffia M. Comparative proteome
18
profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an
epithelial mesenchymal transition associated protein signature. Mol Biosyst. 9 (6): 1127-38
(2013).
IF = 3.183
96. Ambrogi F., Fornili M., Boracchi P., Trerotola M., Relli V., Simeone P., La Sorda R.,
Lattanzio R., Querzoli P., Pedriali M., Piantelli M., Biganzoli E. and Alberti S. Trop-2 is a
determinant of breast cancer survival. PLoS One 9 (10): 1-11 e96993 (2014). Erratum in:
PLoS One. 2014;9(10):e110606.
IF = 3.534
97. Simeone P. and Alberti S. Epigenetic heredity of human height. Phys. Rep. 2 (6): 1-20
e12047 (2014).
IF = to be determined
98. Simeone P., Trerotola M., Urbanella A., Lattanzio R., Ciavardelli D., Di Giuseppe F.,
Eleuterio E., Sulpizio M., Eusebi V., Pession A., Piantelli M. and Alberti S. A unique
four-hub protein cluster associates to glioblastoma progression. PLoS One 9 (7): 1-17
e103030 (2014).
IF = 3.534
Highlights - Malkki H. - Simeone P. and Alberti S. - Proteomic profiling could
facilitate glioblastoma diagnosis. Nature Reviews Neurology (10): 2 (2014). IF:
14.103
99. Li Y., Melnikov A. A., Levenson V., Guerra E., Simeone P., Alberti S. and Deng Y. A
seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer
15 (417): 1-12 (2015) (corresponding author).
IF = 3.360
100. Antolini L., Biganzoli E., Querzoli P., Piantelli M. and Alberti S. Lymph nodes
micrometastases do impact on breast cancer outcome. J. Clin. Oncol. 33 (33): 3977-8
(2015).
IF = 18.430
101. Trerotola M., Relli V., Simeone P. and Alberti S. Epigenetic inheritance and the missing
heritability. Human Genomics-BMC 9 (17): 1-12 (2015).
IF = 2.15
102. Vergara D., Simeone P., Latorre D., Cascione F., Leporatti S., Trerotola M., Anna
Giudetti M., Capobianco L., Lunetti P., Rizzello A., Rinaldi R., Alberti S., Maffia M.
Proteomics analysis of E-cadherin knockdown in epithelial breastcancer cells. J.
Biotechnol. 202: 3-11 (2015).
IF = 2.884
103. Brown D.N., Caffa I., Cirmena G., Piras D., Garuti A., Gallo M., Alberti S., Nencioni A.,
Ballestrero A., Zoppoli G. Squalene epoxidase is a bona fide oncogene by amplification
with clinical relevance in breast cancer. Sci. Reports Jan 18;6:19435 (2016).
IF = 5.578
19
104. Vergara D., Simeone P., Julien F., Trerotola M., Giudetti A., Capobianco L., Tinelli A.,
Bellomo C., Fournier I., Antonio G., Alberti S., Salzet M., Maffia M. Translating
epithelial mesenchymal transition markers into the clinic: novel insights from proteomics
EuPA Open Proteomics 10: 31-41 (2016).
IF = to be determined
105. Guerra E., Trerotola M., Tripaldi R., Aloisi A.L., Simeone P., Sacchetti A., Relli V., D’
Amore A., La Sorda R., Lattanzio R., Piantelli M. and Alberti S. Trop-2 induces tumor
growth through Akt and determines sensitivity to Akt inhibitors. Clin. Cancer Res. Epub
Mar. 28 (2016).
IF = 8.722
106. Simeone P. and Alberti S. HABP2 G534E Mutation in Familial Nonmedullary Thyroid
Cancer. J. Natl. Cancer Inst. 108(8): djw143 (2016).
IF = 12.583
107. Alberti S. Native, sequential protein folding via anchored N- and C- protein termini.
Proc.
Natl.
Acad.
Sci.
USA
113:
23
E3189-91
(2016)
(www.pnas.org/cgi/doi/10.1073/pnas.1602454113 PNAS Early Edition 1-3).
IF = 9.674
108. Guerra E., Cimadamore A., Simeone P., Vacca G., Lattanzio R., Botti G., Gatta V., D’
Aurora M., Simionati B., Piantelli M. and Alberti S. p53, cathepsin D, Bcl-2 are joint
prognostic indicators of breast cancer metastatic spreading. BMC Cancer (submitted).
109. Guerra E., Piantelli M. and Alberti S. Cancer chemoprevention: Evidence of a
nonlinear dose response for the protective effects of resveratrol in humans and mice.
Science Transl. Med. 8:350 350le2 (2016).
IF = 16.264
110. Trerotola M., Tripaldi R., Simeone P., Relli V., Aloisi A.L., Guerra E. and Alberti S.
Giant recursive membrane platforms drive signaling for cell growth (submitted).
111. Ali Z., Aloisi A.L., Guerra E., Trerotola M., Balza E., Simeone P., Ciccarelli F.D.,
Acciarito A., Borsi L., Carnemolla B., Palombo B., Zanna P., Castellani P, Vacca G., La
Sorda R., Lattanzio R., Postina, R., Piantelli M., Zardi L. and Alberti S. Trop-2 recruits
ADAM10 to signaling platforms as an activatory switch for cancer growth. (submitted).
112. Trerotola M., Tripaldi R., Sacchetti A., Havas K., Aloisi A.L., Simeone P., Relli V.,
Guerra E., La Sorda R., Lattanzio R., Vergara D., Fournier I., Salzet M., Piantelli M. and
Alberti S. Trop-2 activates a ubiquitous, dormant layer of cancer growth centered on
PKC, CD9 and cytoskeletal scaffolding (submitted).
113. Trerotola M., Beni L., Antolini L. and Alberti S. Protein-DNA recognition code for helical transcription factors (submitted).
114. Guerra E., Plebani R., Simeone P., Vacca G., Trerotola M., D’ Apolito M., Cantanelli P.,
Acciarito A., La Sorda R., Lattanzio R., Piantelli M. and Alberti S. Trop-2 and Trop-1/EpCAM are a novel class of growth-stimulatory apoptosis inducers (submitted).
20
115. Tripaldi R., Vacca G., Zappacosta R., de Lange R., Weidle U. H., Trerotola M., Lasorda
R., Lattanzio R., Querzoli P., Bianchini E., Angelucci D., Pizzicannella G., Antolini L.,
Nenci I., Piantelli M. and Alberti S.
Oppure
Trerotola M., Tripaldi R., Sacchetti A., Aloisi A.L., Guerra E., Simeone P., Dini F., La Sorda R.,
Lattanzio R., Angelucci D., Pizzicannella G., Bianchini E., Sun X.-F., Di Loreto C., Beltrami
C.A., Piantelli M. and Alberti S.
Trop-2 determines metastatic spreading of human cancer (in preparation).
116. Patassini C., Ferruzzi E., Guerra E., Franceschini R., Leon A., La Sorda R., Lattanzio R.,
Simeone P., Relli V., Trerotola M., Piantelli M., Gion M. and Alberti S. Trop-2 is a
circulating marker of breast cancer. (in preparation).
117. Guerra E., Trerotola M., Tripaldi R., Dini F., La Sorda R., Lattanzio R., Piantelli M. and
Alberti S. Trop-2 is a pathological stage-tailored target for antibody immunotherapy (in
preparation).
21
Total IF (July 2016) = 582.222
Average IF per article = 5.39
Peer reviewed articles (July 2016) = 108
Total Citations
Average Citations per Article
Hirsch (H) index (Apr. 2016)
2767
25.86
29
Work address
Saverio Alberti, MD, PhD
Unit of Cancer Pathology
Center for Excellence in Research on Aging
University “G. D’ Annunzio”
Via Colle dell’ Ara
66013 Chieti Scalo (Chieti), Italy
Phone: (+39) 0871-541.551
Mobile: (+39) 347-3445.123
FAX: (+39) 0871-541.550
E-mail: [email protected]
Skype: saverioalberti